ITM and MTTI Sign Clinical Supply Agreement for n.c.a. Lutetium-177

ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Molecular Targeting Technologies Inc. (MTTI), a clinical stage biotech company focused on developing innovative therapies for rare cancers, today announced the signing of a global clinical supply agreement that provides MTTI with ITM’s medical radioisotope no-carrier-added lutetium-177 (n.c.a. Lu / EndolucinBeta) for the preclinical and clinical development as well as potential commercial production of MTTI’s radiopharmaceutical candidate n.c.a. Lu-EBTATE to treat a range of cancers.

N.c.a. Lu-EBTATE is currently in the clinical development for the treatment of neuroendocrine tumors, a special form of thyroid cancer (Hürthle cell) and a rare type of head and neck cancer (nasopharyngeal cancer). The radiopharmaceutical is designed to be used in Targeted Radionuclide Therapy, a highly precise approach to directly target and destroy tumor tissue with minimal impact to surrounding healthy tissue. N.c.a. Lu-EBTATE consists of a tumor-targeting molecule and ITM’s medical radioisotope n.c.a. Lu, a market-approved, highly pure form of the beta-emitting radioisotope lutetium-177. N.c.a. Lu can be linked to a variety of tumor-specific targeting molecules for the treatment of various cancers and has been successfully used in numerous clinical and commercial radiopharmaceutical cancer treatments.

“This agreement underscores the potential of our n.c.a. lutetium-177 to provide therapeutic value to patients with hard-to-treat tumors and we are pleased to contribute to MTTI’s exciting program,” comments Steffen Schuster, CEO of ITM. “Through our long-term experience in radioisotope technologies, our proprietary pipeline of targeted radiopharmaceuticals and our supply agreements with pharmaceutical companies, we aim to further expand and support the development of Targeted Radionuclide Therapies to improve clinical outcomes and quality of life for patients worldwide.”

MTTI CEO, Chris Pak, said, “We’ve identified a timely and sustainable supply of a key therapeutic ingredient needed for the development and launch of our lead asset Lu-EBTATE and other EB (Evans blue) platform technologies. We are excited to start this collaboration and build what promises to be a great relationship with a reliable and trusted radioisotope supply partner like ITM for the supply of n.c.a. Lu.”

The agreement was executed between MTTI and ITM’s wholly-owned subsidiary ITM Medical Isotopes GmbH.